GERM
Amplify Treatments, Testing and Adv ETF
NAV as of
4 Week: 16.34 - 17.99
52 Week: 16.34 - 18.95
Latest Closing Price
17.28
Premium / Discount
-0.5
Expense Ratio
0.68%
Investment Objective
The investment seeks investment results that generally correlate to the total return performance of the Prime Treatments, Testing and Advancements Index. Under normal circumstances, the fund invests at least 80% of its net assets in U.S.-listed equity securities or ADRs of Treatments, Testing and Advancements Companies. In general, the index seeks to be comprised of companies performing advancements in research, development, and commercialization of treatments or vaccines for infectious diseases, or engaged in the advancement of research, development, manufacturing, and provision of biological tests for patients. The fund is non-diversified.
Main Fund Characteristics
Performance
Period | Performance Returns(%) | Volatility(%) | Risk Adjusted Performance |
---|---|---|---|
YTD | 0.00 | 0.00 | 0.00 |
1 Day | -0.94 | 0.00 | 0.00 |
1 Week | 2.26 | 5.00 | 0.45 |
1 Month | -6.12 | 7.24 | -0.85 |
3 Months | 0.00 | 0.00 | 0.00 |
6 Months | 0.00 | 0.00 | 0.00 |
1 Year | 0.00 | 0.00 | 0.00 |
2 Years | 0.00 | 0.00 | 0.00 |
3 Years | 0.00 | 0.00 | 0.00 |
5 Years | 0.00 | 0.00 | 0.00 |
10 Years | 0.00 | 0.00 | 0.00 |
Price History
Annual Performance Return
2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
Price (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 14.9502 | -34.8980 | -13.5968 |
Nav (%) | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 |
Rank | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 32.0000 | 90.0000 | 100.0000 |
Dividend Frequency
Lastest Dividend
Ex Date | Payment Date | Dividend Payout per unit |
---|---|---|
N.A |
Portfolio Data
Total Number of Holdings: 59
Number of Bond Holdings: 0
Number of Equity Holdings: 54
Total Market Value: 9,631,659
Portfolio Composition
Top 10 Holdings
% Portfolio Weight | Shares Owned | Shares Changed | Market Value | ||
---|---|---|---|---|---|
1 | Moderna Inc | 8.1896 | 8,247 | 0 | 910,716 |
2 | Laboratory Corp of America Holdings | 5.7606 | 2,954 | 0 | 640,604 |
Country Exposure
Regional Exposure
America
Greater Europe
Greater Asia
Market Classification
Market Capitalization
Size | % of portfolio |
---|---|
Giant | 6.89 |
Large | 9.42 |
Medium | 33.37 |
Small | 16.38 |
Micro | 29.76 |
Equity Style Box Breakdown
0 | 0 | 0 | Large |
0 | 0 | 0 | Mid |
0 | 0 | 0 | Small |
Value | Blend | Growth |
Value Measures
Price/Prospective Earnings*
15.1171
Price/Book*
1.5051
Price/Sales*
2.5541
Price/Cash Flow*
11.2690
Dividend Yield*
0.6090
Growth Measures
Long-Term Earnings
6.4887
Historical Earnings
11.1946
Sales Growth
-5.8088
Cash-Flow Growth
-38.4905
Book-Value Growth
1.2885
*Forward-looking based on historical data.
Equity Sector
Number of Bond Holdings
0
Bond Statitics
Detail | Value |
---|---|
Average Effective Duration | 0 |
Average Effective Maturity (Years)* | 0 |
Average Credit Quality | 0 |
Average Weighted Coupon* | 0 |
Average Weighted Price* | 0 |
Bond Style Box Breakdown
0 | 0 | 0 | High | Quality |
0 | 0 | 0 | Med | |
0 | 0 | 0 | Low | |
Ltd | Mod | Ext | ||
Interest-Rate Sensitivity |
Credit Quality
Type | % Bonds |
---|---|
N.A |
Bond Sector
Bond Maturity
% Bonds | |
---|---|
N.A |
Data Source: Morningstar
© 2019 Morningstar. All Rights Reserved. The information, data, analyses and opinions (“Information”) contained herein:
(2) may not be copied or redistributed except as specifically authorised;
(3) do not constitute investment advice;
(4) are provided solely for informational purposes;
(5) are not warranted to be complete, accurate or timely; and
(6) may be drawn from fund data published on various dates.
Morningstar and Phillip Securities Pte Ltd are not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.
For the most up-to-date fund’s data and information, a copy of the fund factsheet, information or prospectus may be obtained from the respective ETF issuer.